Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to ...

BioNTech sails into ASCO with two clinical readouts that underscore its pivot toward oncology beyond vaccines, even as the stock trades under mid-year pressure and investors weigh the pace of the ...

On the other, the oncology pipeline is about to face its most public scrutiny yet at the American Society of Clinical Oncology meeting in Chicago, where new data on pumitamig and gotistobart will ...

4 Reasons Pfizer Could Be a Value Play You Can't Miss BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to ...

An update from BioNTech SE ( (BNTX) ) is now available.

BioNTech (NasdaqGS:BNTX) has drawn fresh attention after shareholders approved expanding its Supervisory Board at the 2026 ...

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, plans to close several production sites, with up to 1,860 jobs affected. The ...

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...

BioNTech’s messenger RNA technology led to a successful Covid-19 vaccine that provides it with plenty of cash for pipeline expansion. The company is deploying some of that capital in a new partnership ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...